{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:23:01Z","timestamp":1793107381373,"version":"4.5.0"},"reference-count":139,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jcf.2022.10.002","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T07:33:09Z","timestamp":1666942389000},"page":"17-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6516-9083","authenticated-orcid":false,"given":"Kevin W.","family":"Southern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1916-0963","authenticated-orcid":false,"given":"Carlo","family":"Castellani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1661-8687","authenticated-orcid":false,"given":"Elise","family":"Lammertyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5494-5438","authenticated-orcid":false,"given":"Alan","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5727-8164","authenticated-orcid":false,"given":"Donald","family":"VanDevanter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"van Koningsbruggen-Rietschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrg","family":"Barben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8372-4607","authenticated-orcid":false,"given":"Amanda","family":"Bevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0253-9678","authenticated-orcid":false,"given":"Edwin","family":"Brokaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1310-3239","authenticated-orcid":false,"given":"Gary J.","family":"Connett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5249-5100","authenticated-orcid":false,"given":"Thomas W.V.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3506-1199","authenticated-orcid":false,"given":"Jane","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Declercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Gartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gramegna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Kashirskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Lowdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halyna","family":"Makukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilip","family":"Nazareth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquelien","family":"Noordhoek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciaran","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Oxley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S.","family":"Raraigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Raynal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jobst","family":"Roehmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Sermet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Shteinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Takawira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van Mourik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Verkleij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"Duff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2022.10.002_bib0001","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0002","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jcf.2015.01.001","article-title":"Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): a new designation and management recommendations for infants with an inconclusive diagnosis following newborn screening","volume":"14","author":"Munck","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0003","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/humu.22981","article-title":"HGVS recommendations for the description of sequence variants: 2016 update","volume":"37","author":"den Dunnen","year":"2016","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jcf.2022.10.002_bib0004","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0005","unstructured":"US CF Foundation J.H.U., The Hospital for Sick Children,. The Clinical and Functional TRanslation of CFTR (CFTR2). 2011. https:\/\/cftr2.org\/Date accessed: 19\/8\/2022"},{"key":"10.1016\/j.jcf.2022.10.002_bib0006","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/humu.23276","article-title":"CFTR-France, a national relational patient database for sharing genetic and phenotypic data associated with rare CFTR variants","volume":"38","author":"Claustres","year":"2017","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jcf.2022.10.002_bib0007","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jcf.2008.03.009","article-title":"Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice","volume":"7","author":"Castellani","year":"2008","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0008","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ng.2745","article-title":"Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene","volume":"45","author":"Sosnay","year":"2013","journal-title":"Nat Genet"},{"issue":"Suppl 2","key":"10.1016\/j.jcf.2022.10.002_bib0009","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S1569-1993(11)60014-3","article-title":"Recommendations for the classification of diseases as CFTR-related disorders","volume":"10","author":"Bombieri","year":"2011","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0010","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/ejhg.2008.136","article-title":"Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders\u2013updated European recommendations","volume":"17","author":"Dequeker","year":"2009","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.jcf.2022.10.002_bib0011","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJM199410133311503","article-title":"A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations","volume":"331","author":"Highsmith","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0012","first-page":"623","article-title":"A novel donor splice site in intron 11 of the CFTR gene, created by mutation 1811+1.6kbA\u2013>G, produces a new exon: high frequency in Spanish cystic fibrosis chromosomes and association with severe phenotype","volume":"56","author":"Chillon","year":"1995","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jcf.2022.10.002_bib0013","doi-asserted-by":"crossref","first-page":"30024","DOI":"10.1074\/jbc.M109.032623","article-title":"Characterization of a disease-associated mutation affecting a putative splicing regulatory element in intron 6b of the cystic fibrosis transmembrane conductance regulator (CFTR) gene","volume":"284","author":"Faa","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jcf.2022.10.002_bib0014","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jcf.2010.08.009","article-title":"A novel donor splice site characterized by CFTR mRNA analysis induces a new pseudo-exon in CF patients","volume":"9","author":"Costantino","year":"2010","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0015","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jcf.2018.10.012","article-title":"Functional characterization and phenotypic spectrum of three recurrent disease-causing deep intronic variants of the CFTR gene","volume":"18","author":"Bergougnoux","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0016","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/gim.2014.194","article-title":"Small-scale high-throughput sequencing-based identification of new therapeutic tools in cystic fibrosis","volume":"17","author":"Bonini","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0017","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jcf.2021.10.011","article-title":"Complete CFTR gene sequencing in 5,058 individuals with cystic fibrosis informs variant-specific treatment","volume":"21","author":"Raraigh","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0018","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jcf.2011.06.011","article-title":"A recurrent deep-intronic splicing CF mutation emphasizes the importance of mRNA studies in clinical practice","volume":"10","author":"Costa","year":"2011","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0019","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/humu.23389","article-title":"Cis variants identified in F508del complex alleles modulate CFTR channel rescue by small molecules","volume":"39","author":"Baatallah","year":"2018","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jcf.2022.10.002_bib0020","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.3390\/ijms23063175","article-title":"The L467F-F508del complex allele hampers pharmacological rescue of mutant CFTR by elexacaftor\/tezacaftor\/ivacaftor in cystic fibrosis patients: the value of the ex vivo nasal epithelial model to address non-responders to CFTR -modulating drugs","volume":"23","author":"Sondo","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2022.10.002_bib0021","doi-asserted-by":"crossref","first-page":"eS8","DOI":"10.1016\/S0929-693X(20)30044-0","article-title":"CFTR gene variants, epidemiology and molecular pathology","volume":"27","author":"Bareil","year":"2020","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.jcf.2022.10.002_bib0022","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.jcf.2022.10.002_bib0023","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/0092-8674(93)90353-R","article-title":"Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis","volume":"73","author":"Welsh","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.jcf.2022.10.002_bib0024","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jcf.2018.11.014","article-title":"The increasing challenge of genetic counseling for cystic fibrosis","volume":"18","author":"Foil","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0025","doi-asserted-by":"crossref","unstructured":"De Boeck K., Amaral M.D. Progress in therapies for cystic fibrosis. The Lancet Respiratory medicine. 2016;4:662\u201374. DOI:10.1016\/S2213-2600(16)00023-0","DOI":"10.1016\/S2213-2600(16)00023-0"},{"key":"10.1016\/j.jcf.2022.10.002_bib0026","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/thx.2009.125088","article-title":"Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data","volume":"65","author":"Derichs","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2022.10.002_bib0027","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-1-61779-117-8_6","article-title":"Nasal potential difference measurements to assess CFTR ion channel activity","volume":"741","author":"Rowe","year":"2011","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jcf.2022.10.002_bib0028","first-page":"55159","article-title":"Forskolin-induced swelling in intestinal organoids: an in vitro assay for assessing drug response in cystic fibrosis patients","volume":"120","author":"Boj","year":"2017","journal-title":"J Vis Exp"},{"key":"10.1016\/j.jcf.2022.10.002_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009100","article-title":"Evaluation of both exonic and intronic variants for effects on RNA splicing allows for accurate assessment of the effectiveness of precision therapies","volume":"16","author":"Joynt","year":"2020","journal-title":"PLoS Genet"},{"key":"10.1016\/j.jcf.2022.10.002_bib0030","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jcf.2022.04.019","article-title":"Caution advised in the use of CFTR modulator treatment for individuals harboring specific CFTR variants","volume":"21","author":"Raraigh","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0031","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/MCP.0000000000000521","article-title":"Theratyping in cystic fibrosis","volume":"24","author":"Crawford","year":"2018","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0032","article-title":"Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis","volume":"1","author":"Skilton","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jcf.2022.10.002_bib0033","article-title":"Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)","volume":"12","author":"Southern","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jcf.2022.10.002_bib0034","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0035","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomized, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2022.10.002_bib0036","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0037","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del Allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0038","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0039","first-page":"32","article-title":"Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis","volume":"24","author":"Aslam","year":"2017","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.jcf.2022.10.002_bib0040","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2\u20135 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0041","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0042","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1164\/rccm.202008-3177OC","article-title":"Ivacaftor in infants aged 4 to <12 months with cystic fibrosis and a gating mutation. results of a two-part phase 3 clinical trial","volume":"203","author":"Davies","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0043","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jcf.2019.03.009","article-title":"An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5years (KLIMB)","volume":"18","author":"Rosenfeld","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0044","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1164\/rccm.201802-0243LE","article-title":"Changes in lung clearance index in preschool-aged patients with cystic fibrosis treated with ivacaftor (goal): a clinical trial","volume":"198","author":"Ratjen","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0045","doi-asserted-by":"crossref","first-page":"2000006","DOI":"10.1183\/13993003.00006-2020","article-title":"An observational study of the lung clearance index throughout childhood in cystic fibrosis: early years matter","volume":"56","author":"Davies","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2022.10.002_bib0046","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jcf.2019.02.007","article-title":"Abnormal preschool Lung Clearance Index (LCI) reflects clinical status and predicts lower spirometry later in childhood in cystic fibrosis","volume":"18","author":"Hardaker","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0047","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2213-2600(18)30460-0","article-title":"Safety, pharmacokinetics, and pharmacodynamics of Lumacaftor and ivacaftor combination therapy in children aged 2\u20135 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study","volume":"7","author":"McNamara","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0048","doi-asserted-by":"crossref","unstructured":"Hoppe J.E., Chilvers M., Ratjen F., McNamara J.J., Owen C.A., Tian S., et\u00a0al. Long-term safety of Lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study. Lancet Respir Med. 2021;9:977\u201388. DOI:10.1016\/S2213-2600(21)00069-2","DOI":"10.1016\/S2213-2600(21)00069-2"},{"key":"10.1016\/j.jcf.2022.10.002_bib0049","unstructured":"European Medicines Agency. Orkambi Summary of Product Characteristics. 2015. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/orkambi-epar-product-information_en.pdf Date accessed: 29\/3\/22"},{"key":"10.1016\/j.jcf.2022.10.002_bib0050","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1126\/scitranslmed.aax2361","article-title":"Prevention of cystic fibrosis: the beginning of the end?","volume":"11","author":"Ferkol","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0051","doi-asserted-by":"crossref","first-page":"eaau7531","DOI":"10.1126\/scitranslmed.aau7531","article-title":"In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis","volume":"11","author":"Sun","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0052","series-title":"Cystic fibrosis agents. Livertox: clinical and research information on drug-induced liver injury","year":"2012"},{"key":"10.1016\/j.jcf.2022.10.002_bib0053","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jcf.2020.07.014","article-title":"Biliary disease and cholecystectomy after initiation of elexacaftor\/ivacaftor\/tezacaftor in adults with cystic fibrosis","volume":"20","author":"Safirstein","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0054","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/jcm10010023","article-title":"Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review","volume":"10","author":"Dagenais","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11926-010-0104-3","article-title":"Drug-related myopathies of which the clinician should be aware","volume":"12","author":"Valiyil","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jcf.2022.10.002_bib0056","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2020.07.023","volume":"20","author":"Davies","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0057","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3390\/jpm11080729","article-title":"Sweat chloride testing and Nasal Potential Difference (NPD) are primary outcome parameters in treatment with Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators","volume":"11","author":"Sermet-Gaudelus","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0058","doi-asserted-by":"crossref","first-page":"L928","DOI":"10.1152\/ajplung.00395.2015","article-title":"Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomy","volume":"310","author":"Birket","year":"2016","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jcf.2022.10.002_bib0059","unstructured":"Papworth Hospital NHS Foundation Trust. Kaftrio: turning around the lives of patients with cystic fibrosis. 2020. https:\/\/royalpapworth.nhs.uk\/our-hospital\/latest-news\/kaftrio-patients-cystic-fibrosis-Alex-StobbsRoyal Date accessed: 29\/3\/22"},{"key":"10.1016\/j.jcf.2022.10.002_bib0060","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jcf.2020.07.002","article-title":"Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis","volume":"20","author":"DiMango","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0061","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1513\/AnnalsATS.201909-671CME","article-title":"The extrapulmonary effects of cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis","volume":"17","author":"Sergeev","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2022.10.002_bib0062","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcf.2022.10.002_bib0063","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0064","article-title":"Sustained glycemic control with ivacaftor in cystic fibrosis-related diabetes","volume":"7","author":"Christian","year":"2019","journal-title":"J Investig Med High Impact Case Rep"},{"key":"10.1016\/j.jcf.2022.10.002_bib0065","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jcf.2015.10.012","article-title":"CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation","volume":"15","author":"Tsabari","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0066","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0067","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1164\/rccm.201405-0882LE","article-title":"Resolution of cystic fibrosis-related diabetes with ivacaftor therapy","volume":"190","author":"Hayes","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0068","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jcf.2017.11.016","article-title":"Effect of Lumacaftor\/ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients","volume":"17","author":"Thomassen","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0069","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1378\/chest.11-2672","article-title":"Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation","volume":"142","author":"Flume","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2022.10.002_bib0070","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0071","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jcf.2018.07.010","article-title":"Continuous glucose monitoring in youth with cystic fibrosis treated with Lumacaftor-ivacaftor","volume":"18","author":"Li","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0072","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0073","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jcf.2021.07.016","article-title":"Continuous glucose monitoring in cystic fibrosis-Benefits, limitations, and opportunities","volume":"20","author":"Chan","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0074","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/BF01957574","article-title":"Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis","volume":"151","author":"Lanng","year":"1992","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.jcf.2022.10.002_bib0075","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1164\/ajrccm.162.3.9904075","article-title":"Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline","volume":"162","author":"Milla","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 27","key":"10.1016\/j.jcf.2022.10.002_bib0076","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/pedi.12732","article-title":"ISPAD Clinical Practice Consensus Guidelines 2018: management of cystic fibrosis-related diabetes in children and adolescents","volume":"19","author":"Moran","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.jcf.2022.10.002_bib0077","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/dc10-1604","article-title":"Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis","volume":"34","author":"Brodsky","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcf.2022.10.002_bib0078","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jcf.2021.01.002","article-title":"Abnormal glucose tolerance and lung function in children with cystic fibrosis. Comparing oral glucose tolerance test and continuous glucose monitoring","volume":"20","author":"Elidottir","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"Suppl 2","key":"10.1016\/j.jcf.2022.10.002_bib0079","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jcf.2019.08.025","article-title":"Continuous glucose monitoring in cystic fibrosis\u2014a practical guide","volume":"18","author":"Chan","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0080","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jcf.2018.03.008","article-title":"Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline","volume":"17","author":"Chan","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0081","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.jand.2020.03.014","article-title":"Effect of CFTR modulators on anthropometric parameters in individuals with cystic fibrosis: an evidence analysis center systematic review","volume":"121","author":"Bailey","year":"2021","journal-title":"J Acad Nutr Diet"},{"key":"10.1016\/j.jcf.2022.10.002_bib0083","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10071527","article-title":"Real-world outcomes of ivacaftor treatment in people with cystic fibrosis: a systematic review","volume":"10","author":"Duckers","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0084","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2018.05.018","article-title":"Energy balance and mechanisms of weight gain with ivacaftor treatment of cystic fibrosis gating mutations","volume":"201","author":"Stallings","year":"2018","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2022.10.002_bib0085","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1038\/ctg.2017.10","article-title":"Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation","volume":"8","author":"Gelfond","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.jcf.2022.10.002_bib0086","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1164\/rccm.201906-1227OC","article-title":"Real-life safety and effectiveness of Lumacaftor-ivacaftor in patients with cystic fibrosis","volume":"201","author":"Burgel","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0087","first-page":"10","article-title":"CFTR modulator therapy with Lumacaftor\/ivacaftor alters plasma concentrations of lipid-soluble vitamins A and E in patients with cystic fibrosis","author":"Sommerburg","year":"2021","journal-title":"Antioxidants (Basel, Switzerland)"},{"key":"10.1016\/j.jcf.2022.10.002_bib0088","article-title":"Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease","volume":"80","author":"Martin","year":"2021","journal-title":"Respir Med Res"},{"key":"10.1016\/j.jcf.2022.10.002_bib0089","unstructured":"Cystic Fibrosis Trust. Emotional and social impact of Kaftrio. 2020. https:\/\/www.cysticfibrosis.org.uk\/sites\/default\/files\/2020-12\/Emotional%20and%20social%20impact%20of%20Kaftrio%20Nov%202020.pdf Date accessed: 28 February 2022"},{"key":"10.1016\/j.jcf.2022.10.002_bib0090","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.psym.2017.04.001","article-title":"Cystic fibrosis transmembrane regulator modulators: implications for the management of depression and anxiety in cystic fibrosis","volume":"58","author":"Talwalkar","year":"2017","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jcf.2022.10.002_bib0091","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.psym.2020.06.021","article-title":"Trikafta and psychopathology in cystic fibrosis: a case report","volume":"61","author":"Tindell","year":"2020","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jcf.2022.10.002_bib0092","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jcf.2017.05.008","article-title":"Worsening anxiety and depression after initiation of Lumacaftor\/ivacaftor combination therapy in adolescent females with cystic fibrosis","volume":"16","author":"McKinzie","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0093","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jcf.2021.10.002","article-title":"Mental status changes during elexacaftor\/tezacaftor \/ivacaftor therapy","volume":"21","author":"Heo","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0094","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/thoraxjnl-2014-205983","article-title":"Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries","volume":"69","author":"Quittner","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2022.10.002_bib0095","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1177\/1060028013514846","article-title":"Prevalence of depression and antidepressant therapy use in a pediatric cystic fibrosis population","volume":"48","author":"Ploessl","year":"2014","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jcf.2022.10.002_bib0096","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/ppul.21238","article-title":"Depressive symptoms in children with cystic fibrosis and parents and its effects on adherence to airway clearance","volume":"45","author":"Smith","year":"2010","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2022.10.002_bib0097","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jcf.2018.02.005","article-title":"Implementing the International Committee on Mental Health in Cystic Fibrosis (ICMH) guidelines: screening accuracy and referral-treatment pathways","volume":"17","author":"Verkleij","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0098","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/thoraxjnl-2015-207488","article-title":"International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety","volume":"71","author":"Quittner","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2022.10.002_bib0099","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/ppul.22990","article-title":"Depression, illness severity, and healthcare utilization in cystic fibrosis","volume":"49","author":"Snell","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2022.10.002_bib0100","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jcf.2020.07.020","article-title":"Decreased survival in cystic fibrosis patients with a positive screen for depression","volume":"20","author":"Schechter","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0101","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2019.09.018","article-title":"Adherence to Lumacaftor-ivacaftor therapy in patients with cystic fibrosis in France","volume":"19","author":"Olivereau","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0102","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jcf.2018.10.009","article-title":"Failure to conceive in women with CF is associated with pancreatic insufficiency and advancing age","volume":"18","author":"Shteinberg","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0103","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.chest.2021.07.024","article-title":"Cohen-Cymberknoh M. fertility and pregnancy in cystic fibrosis","volume":"160","author":"Shteinberg","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2022.10.002_bib0104","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/1471-0528.16957","article-title":"Pregnancy rates and outcomes in women with cystic fibrosis in the UK: comparisons with the general population before and after the introduction of disease-modifying treatment, 2003-17","volume":"129","author":"Esan","year":"2022","journal-title":"BJOG"},{"key":"10.1016\/j.jcf.2022.10.002_bib0105","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jcf.2020.12.011","article-title":"Elexacafator\/tezacaftor\/ivacaftor resolves subfertility in females with CF: a two center case series","volume":"20","author":"O'Connor","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0106","first-page":"e17427","article-title":"Cystic fibrosis transmembrane conductance regulator modulators during pregnancy: a case series","volume":"13","author":"Kendle","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.jcf.2022.10.002_bib0107","unstructured":"Cystic Fibrosis Foundation. Clinical Considerations: fertility and CFTR Modulators. 2022. https:\/\/www.ecfs.eu\/sites\/default\/files\/Clinical%20Considerations%20Fertility%20and%20Modulators.04122022.pdf Date accessed: 9 May 2022"},{"key":"10.1016\/j.jcf.2022.10.002_bib0108","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jcf.2017.07.017","article-title":"Sexual and reproductive health behaviors and experiences reported by young women with cystic fibrosis","volume":"17","author":"Kazmerski","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0109","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.contraception.2020.02.006","article-title":"Contraceptive use among women with cystic fibrosis: a pilot study linking reproductive health questions to the Cystic Fibrosis Foundation National Patient Registry","volume":"101","author":"Godfrey","year":"2020","journal-title":"Contraception"},{"key":"10.1016\/j.jcf.2022.10.002_bib0110","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(01)64278-2","article-title":"Normal vas deferens in fetuses with cystic fibrosis","volume":"158","author":"Gaillard","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.jcf.2022.10.002_bib0111","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.jcf.2017.09.006","article-title":"Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation","volume":"17","author":"Trimble","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0112","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jcf.2020.02.018","article-title":"Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators\u2014an international survey","volume":"19","author":"Nash","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0113","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2021.03.006","article-title":"Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation","volume":"20","author":"Taylor-Cousar","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0114","unstructured":"European Medicines Agency. Kaftrio Summary of Product Characteristics. 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kaftrio Date accessed: 1 July 2021"},{"key":"10.1016\/j.jcf.2022.10.002_bib0115","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jcf.2018.05.009","article-title":"Measured fetal and neonatal exposure to Lumacaftor and ivacaftor during pregnancy and while breastfeeding","volume":"17","author":"Trimble","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0116","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S2213-2600(14)70100-6","article-title":"Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"2","author":"Kerem","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0117","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0118","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/ppul.25285","article-title":"Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype","volume":"56","author":"McGarry","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2022.10.002_bib0119","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jcf.2013.12.003","article-title":"The relative frequency of CFTR mutation classes in European patients with cystic fibrosis","volume":"13","author":"De Boeck","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0120","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3390\/jpm11050421","article-title":"Personalized medicine based on nasal epithelial cells: comparative studies with rectal biopsies and intestinal organoids","volume":"11","author":"Silva","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0121","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.celrep.2019.01.068","article-title":"Rectal organoids enable personalized treatment of cystic fibrosis","volume":"26","author":"Berkers","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.jcf.2022.10.002_bib0122","doi-asserted-by":"crossref","first-page":"1902426","DOI":"10.1183\/13993003.02426-2019","article-title":"Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis","volume":"57","author":"Ramalho","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2022.10.002_bib0123","doi-asserted-by":"crossref","first-page":"344ra84","DOI":"10.1126\/scitranslmed.aad8278","article-title":"Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis","volume":"8","author":"Dekkers","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0124","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3390\/jpm11121376","article-title":"Prediction of real-world long-term outcomes of people with CF homozygous for the F508del mutation treated with CFTR modulators","volume":"11","author":"Muilwijk","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.jcf.2022.10.002_bib0125","doi-asserted-by":"crossref","first-page":"L119","DOI":"10.1152\/ajplung.00639.2020","article-title":"CFTR function and clinical response to modulators parallel nasal epithelial organoid swelling","volume":"321","author":"Anderson","year":"2021","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jcf.2022.10.002_bib0126","doi-asserted-by":"crossref","first-page":"2100908","DOI":"10.1183\/13993003.00908-2021","article-title":"Theratyping cystic fibrosis in vitro in ALI culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells","volume":"58","author":"Sette","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2022.10.002_bib0127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcf.2019.11.011","article-title":"Expanding access to CFTR modulators for rare mutations: the utility of n-of-1 trials","volume":"19","author":"Magaret","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0128","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/bmj.316.7147.1771","article-title":"Clinical outcome in relation to care in centers specializing in cystic fibrosis: cross sectional study","volume":"316","author":"Mahadeva","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.jcf.2022.10.002_bib0129","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jcf.2022.04.009","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor among cystic fibrosis lung transplant recipients","volume":"21","author":"Ramos","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0130","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.healun.2019.03.009","article-title":"Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment\u2014a consensus report from the Pulmonary Council of the ISHLT","volume":"38","author":"Verleden","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jcf.2022.10.002_bib0131","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000339627","article-title":"Impact of sinus surgery on pseudomonal airway colonization, bronchiolitis obliterans syndrome and survival in cystic fibrosis lung transplant recipients","volume":"86","author":"Vital","year":"2013","journal-title":"Respiration"},{"key":"10.1016\/j.jcf.2022.10.002_bib0132","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.jtcvs.2017.11.031","article-title":"Association of body mass index with lung transplantation survival in the United States following implementation of the lung allocation score","volume":"155","author":"Fernandez","year":"2018","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jcf.2022.10.002_bib0133","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jdiacomp.2010.03.002","article-title":"The importance of glycemic control: how low should we go with HbA1c? Start early, go safe, go low","volume":"25","author":"Benhalima","year":"2011","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.jcf.2022.10.002_bib0134","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/thoraxjnl-2017-210473","article-title":"The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers","volume":"73","author":"Rowbotham","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2022.10.002_bib0135","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1378\/chest.123.1.37","article-title":"GI complications after lung transplantation in patients with cystic fibrosis","volume":"123","author":"Gilljam","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2022.10.002_bib0136","first-page":"S1568","article-title":"Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor\/tezacaftor\/ivacaftor","volume":"13","author":"Fajac","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0137","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcf.2020.11.006","article-title":"Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome\/cystic fibrosis screen positive, inconclusive diagnosis (CRMS\/CFSPID)","volume":"20","author":"Barben","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0138","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jcf.2022.04.007","article-title":"Current prices versus minimum costs of production for CFTR modulators","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.002_bib0139","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/j.jcf.2022.03.006","article-title":"Global access to affordable CFTR modulator drugs: time for action!","volume":"21","author":"Zampoli","year":"2022","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322013856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322013856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:47:39Z","timestamp":1761601659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199322013856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":139,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1569199322013856"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2022.10.002","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2022.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}